CY1119631T1 - Σταθερες ρυθμισεις φαρμακων για τη θεραπεια των αιματοποιητικων καρκινων και των πολλαπλασιαστικων διαταραχων - Google Patents

Σταθερες ρυθμισεις φαρμακων για τη θεραπεια των αιματοποιητικων καρκινων και των πολλαπλασιαστικων διαταραχων

Info

Publication number
CY1119631T1
CY1119631T1 CY20171101251T CY171101251T CY1119631T1 CY 1119631 T1 CY1119631 T1 CY 1119631T1 CY 20171101251 T CY20171101251 T CY 20171101251T CY 171101251 T CY171101251 T CY 171101251T CY 1119631 T1 CY1119631 T1 CY 1119631T1
Authority
CY
Cyprus
Prior art keywords
disorders
diversity
adjustments
treatment
blood cancer
Prior art date
Application number
CY20171101251T
Other languages
English (en)
Inventor
Arthur Louie
Christine Swenson
Lawrence Mayer
Andrew Janoff
Original Assignee
Celator Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119631(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celator Pharmaceuticals, Inc. filed Critical Celator Pharmaceuticals, Inc.
Publication of CY1119631T1 publication Critical patent/CY1119631T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Abstract

Στο παρόν παρέχονται μέθοδοι θεραπείας καρκίνου με χορήγηση μιας φαρμακευτικής σύνθεσης που περιλαμβάνει σταθερή, μη-ανταγωνιστική γραμμομοριακή αναλογία κυταραβίνης και ανθρακυκλίνης. Τέτοιες μέθοδοι είναι ιδιαίτερα χρήσιμες στη θεραπεία ασθενών με προχωρημένους αιματολογικούς καρκίνους ή πολλαπλασιαστικές διαταραχές.
CY20171101251T 2007-02-16 2017-11-29 Σταθερες ρυθμισεις φαρμακων για τη θεραπεια των αιματοποιητικων καρκινων και των πολλαπλασιαστικων διαταραχων CY1119631T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90177207P 2007-02-16 2007-02-16
US96519607P 2007-08-17 2007-08-17
PCT/US2008/054168 WO2008101214A2 (en) 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Publications (1)

Publication Number Publication Date
CY1119631T1 true CY1119631T1 (el) 2018-04-04

Family

ID=39690832

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101251T CY1119631T1 (el) 2007-02-16 2017-11-29 Σταθερες ρυθμισεις φαρμακων για τη θεραπεια των αιματοποιητικων καρκινων και των πολλαπλασιαστικων διαταραχων

Country Status (20)

Country Link
US (2) US20100303895A1 (el)
EP (3) EP4046640A1 (el)
JP (1) JP5314600B2 (el)
KR (2) KR20150038752A (el)
CN (1) CN105998046A (el)
AU (1) AU2008216083B2 (el)
CA (1) CA2678332C (el)
CY (1) CY1119631T1 (el)
DK (2) DK2120568T3 (el)
ES (2) ES2650167T3 (el)
FR (1) FR22C1034I2 (el)
HK (1) HK1253378A1 (el)
HR (1) HRP20220428T3 (el)
HU (2) HUE058334T2 (el)
NL (1) NL301185I2 (el)
NO (1) NO2120568T3 (el)
PL (2) PL3300601T3 (el)
PT (2) PT3300601T (el)
SI (1) SI3300601T1 (el)
WO (1) WO2008101214A2 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036822A1 (en) * 2008-09-24 2010-04-01 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
CN104114156A (zh) 2011-10-21 2014-10-22 切拉托尔制药公司 冻干脂质体
US20140154304A1 (en) * 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
WO2015127172A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
MY193531A (en) 2015-11-11 2022-10-18 Celator Pharmaceuticals Inc Assays and methods for selecting a treatment regimen for a subject with leukemia
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019023873A1 (zh) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物
MX2021003527A (es) * 2018-09-25 2021-05-27 Celator Pharmaceuticals Inc Tratamiento de baja intensidad de trastornos hematologicos.
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
AU2003226361B2 (en) * 2002-11-06 2009-01-22 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
EP1575582A4 (en) * 2002-11-06 2009-03-11 Wyeth Corp COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
ES2388064T3 (es) 2004-04-22 2012-10-08 Celator Pharmaceuticals, Inc. Formulaciones liposomales de agentes de antraciclina y análogos de citidina
SE0402025D0 (sv) 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
WO2007076117A2 (en) * 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof

Also Published As

Publication number Publication date
EP2120568A4 (en) 2010-04-21
SI3300601T1 (sl) 2022-05-31
US20100303895A1 (en) 2010-12-02
CN105998046A (zh) 2016-10-12
DK2120568T3 (en) 2017-12-11
EP2120568B1 (en) 2017-11-15
CA2678332C (en) 2015-06-02
NL301185I2 (nl) 2022-07-21
ES2650167T3 (es) 2018-01-17
PL2120568T3 (pl) 2018-03-30
JP2010519224A (ja) 2010-06-03
PT2120568T (pt) 2017-12-04
HRP20220428T3 (hr) 2022-05-27
EP3300601B1 (en) 2022-01-12
AU2008216083A2 (en) 2009-09-24
AU2008216083A1 (en) 2008-08-21
US8092828B2 (en) 2012-01-10
EP2120568A2 (en) 2009-11-25
ES2909903T3 (es) 2022-05-10
FR22C1034I1 (fr) 2022-09-09
AU2008216083B2 (en) 2014-02-06
HUS2200032I1 (hu) 2022-07-28
PL3300601T3 (pl) 2022-05-02
KR20100014441A (ko) 2010-02-10
US20080199515A1 (en) 2008-08-21
WO2008101214A2 (en) 2008-08-21
KR20150038752A (ko) 2015-04-08
FR22C1034I2 (fr) 2023-06-30
HUE058334T2 (hu) 2022-07-28
JP5314600B2 (ja) 2013-10-16
DK3300601T3 (da) 2022-03-21
CA2678332A1 (en) 2008-08-21
PT3300601T (pt) 2022-04-21
NO2120568T3 (el) 2018-04-14
EP3300601A1 (en) 2018-04-04
EP4046640A1 (en) 2022-08-24
WO2008101214A3 (en) 2008-11-20
HK1253378A1 (zh) 2019-06-14

Similar Documents

Publication Publication Date Title
CY1119631T1 (el) Σταθερες ρυθμισεις φαρμακων για τη θεραπεια των αιματοποιητικων καρκινων και των πολλαπλασιαστικων διαταραχων
CY1120135T1 (el) Αναστολεις κινασης τυροσινης bruton
CY1120555T1 (el) Νανοσωματιδιο που περιλαμβανει ραπαμυκινη και αλβουμινη ως αντικαρκινικος παραγοντας
CY1117725T1 (el) Νανοσωματιδια πακλιταξελης και λευκωματινης σε συνδυασμο με μπεβασιζουμαμπη εναντι καρκινου
CY1121735T1 (el) 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου
CY1120445T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
CY1124166T1 (el) Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες
CY1121125T1 (el) Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης
WO2007050784A3 (en) Fixed ratio drug combination treatments for solid tumors
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
CY1115782T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
CY1114708T1 (el) Παραγωγα πυραζολο-κιναζολινης, διαδικασια για την παρασκευη τους και η χρηση τους ως αναστολεων κινασης
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
CY1111065T1 (el) Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1113136T1 (el) Αντιμετωπιση των διαταραχων των χονδρων με ton fgf-18
NO20090623L (no) Forbindelser for behandling av proliferative lidelser
WO2008027445A3 (en) Combination with bis(thiohydrazide amides) for treating cancer
AR059982A1 (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
BR112018011177A2 (pt) conjugados de citarabina para terapia de câncer
CY1121628T1 (el) 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης
CY1121667T1 (el) Παραγοντες για θεραπεια τριπλα αρνητικου καρκινου μαστου